申请人:Oxford William Alexander
公开号:US20050176791A1
公开(公告)日:2005-08-11
The present invention relates to compounds which include compounds of the formula I:
or a pharmaceutically acceptable salt thereof, wherein one of R
1
and R
4
is selected from the group consisting of H, and optionally substituted C
1-6
alkyl, C
3-7
cycloalkyl, C
3-7
cycloalkyl-C
1-4
alkyl, and phenyl-C
1-4
alkyl;
and the other of R
1
and R
4
is an optionally substituted C
9-14
aryl group;
R
2
and R
3
are either:
(i) independently selected from H, R, R′, SO
2
R, C(═O)R, (CH
2
)
n
NR
5
R
6
, where n is from 1 to 4 and R
5
and R
6
are independently selected from H and R, where R is optionally substituted C
1-4
alkyl, and R′ is optionally substituted phenyl-C
1-4
alkyl, or
(ii) together with the nitrogen atom to which they are attached, form an optionally substituted C
5-7
heterocyclic group. The compounds are useful in the treatment of conditions including conditions which can be alleviated by antagonism of a 5-HT
2B
receptor such as GI disorders and congestive heart failure.
本发明涉及包括公式I化合物的化合物:或其药用可接受的盐,其中R1和R4之一选自由H、以及可选地取代的C1-6烷基、C3-7环烷基、C3-7环烷基-C1-4烷基和苯基-C1-4烷基组成的组;而R1和R4中的另一个是可选地取代的C9-14芳基基团;R2和R3是:(i)独立地选自H、R、R′、SO2R、C(═O)R、(CH2)nNR5R6,其中n是从1到4,而R5和R6独立地选自H和R,其中R是可选地取代的C1-4烷基,而R′是可选地取代的苯基-C1-4烷基,或(ii)与它们所连接的氮原子一起,形成一个可选地取代的C5-7杂环基团。这些化合物可用于治疗包括可以通过对抗5-HT2B受体而缓解的条件,如胃肠道疾病和充血性心力衰竭。